Mitsubishi Tanabe Ph (MTZXF) 14.4900 $MTZXF
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
M2 - Tue Jun 17, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mr4qd6/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023" report to their offering. Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly's Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida's Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Japan. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Needs and Opportunities 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/mr...harmapoint
Ischemic Stroke - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2fmkd/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - BioTime, Inc. - Athersys, Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - FibroGen, Inc. - Panacea Pharmaceuticals, Inc. - Acorda Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Celgene Corporation - Neuralstem, Inc. - Mesoblast Limited - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - Huons Co., Ltd. - NeuroVive Pharmaceutical AB - Digna Biotech, S.L. - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Virogenomics, Inc. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. - Tarix Pharmaceuticals LTD. - International Biotechnology Center Generium - MediaPharma s.r.l. For more information visit http://www.researchandmarkets.com/research/c2...mic_stroke
Secondary Hyperparathyroidism - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4wbj79/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/4wbj79/secondary
2014 Report on the International Diabetic Nephropathy Market - Forecasts to 2018
M2 - Mon Jun 09, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xgb23/global_diabetic) has announced the addition of the "2014 Report on the International Diabetic Nephropathy Market - Forecasts to 2018" report to their offering. Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control. This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market. The report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Snapshot 08. Rate of Incidence and Prevalence 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - AbbVie - Ampio - Astellas Pharma - Bayer - ChemoCentryx - GenKyoTex - Glycadia Pharmaceuticals - IMMD - Merck & Co - Mesoblast - Mitsubishi Tanabe Pharma - NOXXON Pharma - NephroGenex - Novartis - Novo Nordisk - OncoImmune - Pfizer - PhytoHealth - Questcor - Reata - Sanofi. For more information visit http://www.researchandmarkets.com/research/3x...l_diabetic
Urinary Incontinence - Pipeline Review, H1 2014: 14 Companies Profiled
M2 - Thu May 29, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pschh7/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Allergan, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - Cook Medical Incorporated - Dignity Sciences Ltd. - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - Melior Discovery, Inc. - Mitsubishi Tanabe Pharma Corporation - Recordati S.p.A. - TheraVida, Inc. For more information visit http://www.researchandmarkets.com/research/pschh7/urinary
Insomnia - Pipeline Review, H1 2014: Includes 16 Company Profiles
M2 - Thu May 29, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lslnv2/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Abeille Pharmaceuticals - Actelion - Angelini - Eisai - Evotec - Grupo Ferrer Internacional - Heptares Therapeutics - Intec Pharma - IntelGenx - Intra-Cellular Therapies - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe Pharma - Neurim Pharmaceuticals - Novartis - Somnus Therapeutics For more information visit http://www.researchandmarkets.com/research/lslnv2/insomnia
Global Generic Drugs Market 2014-2018: Actavis, Mylan, Novartis International, STADA Arzneimittel & Teva Pharmaceuticals Dominate the $300+ Billion Industry
M2 - Mon May 26, 3:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db5ngc/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018: Actavis, Mylan, Novartis International, STADA Arzneimittel & Teva Pharmaceuticals Dominate the $300 Billion Industry" report to their offering. The report states that one of the main challenges in the market is intense competition among vendors, which decreases the profit margins and increases pricing pressure. Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. According to the report, one of the major drivers is the patent expiry of top-selling drugs, which can push the introduction of cheap generic drugs in the market. It is expected that branded drugs with sales of up to US$135 billion will go off-patent by 2015. Key vendors dominating this space include - Actavis plc - Mylan Inc. - Novartis International AG (Sandoz) - STADA Arzneimittel AG - Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are - 3SBio Inc. - Amgen Inc. - Apotex Inc. - AstraZeneca plc - Aurobindo Pharma Ltd. - Baxter International Inc. - Berlin-Chemie AG - Biocon Ltd. - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celltrion Inc. - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Dr. Reddy's Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Gedeon Richter plc - GlaxoSmithKline plc - Hospira Inc. - Impax Laboratories Inc. - Intas Pharmaceuticals Ltd. - Lupin Ltd. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Par Pharmaceutical Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Roche Holding AG - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/db...al_generic
Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting
M2 - Fri May 23, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34ctjx/keryxs_zerenex) has announced the addition of the "Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting" report to their offering. Zerenex is an oral ferric citrate-based phosphate binder that Keryx developed for use in the treatment of the elevated phosphorous levels experienced by patients undergoing dialysis for chronic renal failure. Hyperphosphatemia upsets the finely tuned balance between calcium and phosphorus in the body, often referred to as the Ca X PO4 product. Those disruptions ultimately affect bone health. Similarly, chronic renal disease is associated with chronic anemia. Excessive blood loss is one cause in the dialysis setting. The result is iron deficiency. Zerenex is uniquely positioned to treat both hyperphosphatemia and iron deficiency. As such, it is unique amongst phosphate binders. Key Topics Covered: The Metabolic disturbances of chronic kidney disease - Hyperphosphatemia of chronic kidney disease - Anemia of chronic kidney disease Zerenex (Ferric citrate/JTT-751) - Preclinical and early phase datarationale for use - Completed clinical trials - Other trials (ClinicalTrials.gov) Clinical and regulatory Discussion - What do these basic data tell us about Zerenex and its competitive profile? - IronZerenex's two-for-the price of one' advantage - Regulatory discussion - In summarythe implications for Zerenex Market opportunity - Epidemiology (USRDS, 2013) - Pipeline - Issues Summary opinion Companies Mentioned: - AbbVie - Amgen - Japan Tobacco International - Keryx Pharmaceuticals - Kissai Pharma - Mitsubishi Tanabe Pharma - Panioun & BF Biotech - Sanofi/Genzyme - Shire - Torii - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/34...xs_zerenex About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Surveyed U.S. Psychiatrists Would Prescribe EnVivo Pharmaceuticals' Encenicline to 25 Percent of their Patients with Cognitive Impairment Associated with Schizophrenia
PR Newswire - Mon Mar 31, 9:00AM CDT
Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia (CIAS). Assuming its promising--albeit preliminary--clinical profile is confirmed in ongoing Phase III studies, encenicline could become the first-ever therapy approved to treat this condition, fulfilling a major unmet need in the clinical management of schizophrenia. Surveyed psychiatrists also project patient shares of up to 20 percent for other emerging CIAS drugs, including AbbVie's ABT-126, Omeros's OMS-824, and Avineuro Pharmaceuticals' AVN-211.
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC"
and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company" , a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement" involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC" and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser" .
Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
M2 - Thu Sep 12, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2s635/competitor) has announced the addition of the "Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors" report to their offering. The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule inhibitors of Poly-Adenyl-Ribose Polymerase (PARP) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi's PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors. The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - AbbVie - Angion Biomedica - AstraZeneca - BioMarin Pharmaceuticals - Clovis Oncology - Eisai - Eternity Bioscience - Inotek Pharmaceuticals - Mitsubishi Tanabe Pharma - Nerviano Medical Sciences - NewGen Therapeutics - Tesaro - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/d2s635/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
M2 - Tue Jun 17, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mr4qd6/pharmapoint) has announced the addition of the "PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023" report to their offering. Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly's Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida's Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Japan. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Needs and Opportunities 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/mr...harmapoint
Ischemic Stroke - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2fmkd/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - BioTime, Inc. - Athersys, Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Merck & Co., Inc. - FibroGen, Inc. - Panacea Pharmaceuticals, Inc. - Acorda Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Celgene Corporation - Neuralstem, Inc. - Mesoblast Limited - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - Huons Co., Ltd. - NeuroVive Pharmaceutical AB - Digna Biotech, S.L. - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Virogenomics, Inc. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. - Tarix Pharmaceuticals LTD. - International Biotechnology Center Generium - MediaPharma s.r.l. For more information visit http://www.researchandmarkets.com/research/c2...mic_stroke
Secondary Hyperparathyroidism - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4wbj79/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/4wbj79/secondary
2014 Report on the International Diabetic Nephropathy Market - Forecasts to 2018
M2 - Mon Jun 09, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xgb23/global_diabetic) has announced the addition of the "2014 Report on the International Diabetic Nephropathy Market - Forecasts to 2018" report to their offering. Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control. This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market. The report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Snapshot 08. Rate of Incidence and Prevalence 09. Geographical Segmentation 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Trends and their Impact 17. Vendor Landscape 18. Key Vendor Analysis 19. Other Reports in this Series Companies Mentioned: - AbbVie - Ampio - Astellas Pharma - Bayer - ChemoCentryx - GenKyoTex - Glycadia Pharmaceuticals - IMMD - Merck & Co - Mesoblast - Mitsubishi Tanabe Pharma - NOXXON Pharma - NephroGenex - Novartis - Novo Nordisk - OncoImmune - Pfizer - PhytoHealth - Questcor - Reata - Sanofi. For more information visit http://www.researchandmarkets.com/research/3x...l_diabetic
Urinary Incontinence - Pipeline Review, H1 2014: 14 Companies Profiled
M2 - Thu May 29, 7:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pschh7/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Incontinence and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Incontinence - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Incontinence and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - Allergan, Inc. - Astellas Pharma Inc. - Beech Tree Labs, Inc. - Cook Medical Incorporated - Dignity Sciences Ltd. - Evotec AG - FemmePharma Global Healthcare, Inc. - Innovacell Biotechnologie AG - Melior Discovery, Inc. - Mitsubishi Tanabe Pharma Corporation - Recordati S.p.A. - TheraVida, Inc. For more information visit http://www.researchandmarkets.com/research/pschh7/urinary
Insomnia - Pipeline Review, H1 2014: Includes 16 Company Profiles
M2 - Thu May 29, 6:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lslnv2/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Abeille Pharmaceuticals - Actelion - Angelini - Eisai - Evotec - Grupo Ferrer Internacional - Heptares Therapeutics - Intec Pharma - IntelGenx - Intra-Cellular Therapies - Johnson & Johnson - Merck & Co - Mitsubishi Tanabe Pharma - Neurim Pharmaceuticals - Novartis - Somnus Therapeutics For more information visit http://www.researchandmarkets.com/research/lslnv2/insomnia
Global Generic Drugs Market 2014-2018: Actavis, Mylan, Novartis International, STADA Arzneimittel & Teva Pharmaceuticals Dominate the $300+ Billion Industry
M2 - Mon May 26, 3:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db5ngc/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018: Actavis, Mylan, Novartis International, STADA Arzneimittel & Teva Pharmaceuticals Dominate the $300 Billion Industry" report to their offering. The report states that one of the main challenges in the market is intense competition among vendors, which decreases the profit margins and increases pricing pressure. Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. According to the report, one of the major drivers is the patent expiry of top-selling drugs, which can push the introduction of cheap generic drugs in the market. It is expected that branded drugs with sales of up to US$135 billion will go off-patent by 2015. Key vendors dominating this space include - Actavis plc - Mylan Inc. - Novartis International AG (Sandoz) - STADA Arzneimittel AG - Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are - 3SBio Inc. - Amgen Inc. - Apotex Inc. - AstraZeneca plc - Aurobindo Pharma Ltd. - Baxter International Inc. - Berlin-Chemie AG - Biocon Ltd. - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celltrion Inc. - Cipla Ltd. - Coherus Biosciences Inc. - Daiichi Sankyo Co. Ltd. - Dr. Reddy's Laboratories Ltd. - Emcure Pharmaceuticals Ltd. - Gedeon Richter plc - GlaxoSmithKline plc - Hospira Inc. - Impax Laboratories Inc. - Intas Pharmaceuticals Ltd. - Lupin Ltd. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Par Pharmaceutical Inc. - Pfizer Inc. - Ranbaxy Laboratories Ltd. - Roche Holding AG - Sanofi S.A. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/db...al_generic
Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting
M2 - Fri May 23, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34ctjx/keryxs_zerenex) has announced the addition of the "Keryx's Zerenex - Novel phosphate binder for use in the dialysis setting" report to their offering. Zerenex is an oral ferric citrate-based phosphate binder that Keryx developed for use in the treatment of the elevated phosphorous levels experienced by patients undergoing dialysis for chronic renal failure. Hyperphosphatemia upsets the finely tuned balance between calcium and phosphorus in the body, often referred to as the Ca X PO4 product. Those disruptions ultimately affect bone health. Similarly, chronic renal disease is associated with chronic anemia. Excessive blood loss is one cause in the dialysis setting. The result is iron deficiency. Zerenex is uniquely positioned to treat both hyperphosphatemia and iron deficiency. As such, it is unique amongst phosphate binders. Key Topics Covered: The Metabolic disturbances of chronic kidney disease - Hyperphosphatemia of chronic kidney disease - Anemia of chronic kidney disease Zerenex (Ferric citrate/JTT-751) - Preclinical and early phase datarationale for use - Completed clinical trials - Other trials (ClinicalTrials.gov) Clinical and regulatory Discussion - What do these basic data tell us about Zerenex and its competitive profile? - IronZerenex's two-for-the price of one' advantage - Regulatory discussion - In summarythe implications for Zerenex Market opportunity - Epidemiology (USRDS, 2013) - Pipeline - Issues Summary opinion Companies Mentioned: - AbbVie - Amgen - Japan Tobacco International - Keryx Pharmaceuticals - Kissai Pharma - Mitsubishi Tanabe Pharma - Panioun & BF Biotech - Sanofi/Genzyme - Shire - Torii - Vifor Pharma For more information visit http://www.researchandmarkets.com/research/34...xs_zerenex About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Surveyed U.S. Psychiatrists Would Prescribe EnVivo Pharmaceuticals' Encenicline to 25 Percent of their Patients with Cognitive Impairment Associated with Schizophrenia
PR Newswire - Mon Mar 31, 9:00AM CDT
Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia (CIAS). Assuming its promising--albeit preliminary--clinical profile is confirmed in ongoing Phase III studies, encenicline could become the first-ever therapy approved to treat this condition, fulfilling a major unmet need in the clinical management of schizophrenia. Surveyed psychiatrists also project patient shares of up to 20 percent for other emerging CIAS drugs, including AbbVie's ABT-126, Omeros's OMS-824, and Avineuro Pharmaceuticals' AVN-211.
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC"
and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC. Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"
, a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement" involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC" and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser" . Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
M2 - Thu Sep 12, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2s635/competitor) has announced the addition of the "Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors" report to their offering. The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule inhibitors of Poly-Adenyl-Ribose Polymerase (PARP) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi's PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors. The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - AbbVie - Angion Biomedica - AstraZeneca - BioMarin Pharmaceuticals - Clovis Oncology - Eisai - Eternity Bioscience - Inotek Pharmaceuticals - Mitsubishi Tanabe Pharma - Nerviano Medical Sciences - NewGen Therapeutics - Tesaro - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/d2s635/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
